You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石药业(02616.HK)普拉替尼胶囊新药上市申请获药监局批准
阿思达克 03-24 17:17
基石药业(02616.HK)公布,普拉替尼胶囊「普吉华」的新药上市申请已获得中国国家药品监督管理局批准,用於既往接受过含铂化疗的转染重排(RET)基因融合阳性的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的治疗。

该产品由基石药业合作夥伴Blueprint Medicines公司开发,是中国第一个获批上市的选择性RET抑制剂,同时也是基石药业首个商业化上市的产品。

董事长兼首席执行官江宁军表示,将继续全力推进普吉华在中国的研发,更广泛地评估其在包括一线NSCLC、甲状腺癌和其它实体瘤患者中的疗效。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account